Prokarium Names Eldered as Chairman of the Board
5 October 2021 - - UK-based biopharmaceutical company Prokarium has appointed Thomas Eldered as chairman of the board, the company said.

Thomas Eldered succeeds Steve Chatfield, PhD, who will remain a Member of Prokarium's board of directors.

Eldered is president of Flerie Invest, which finances venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges.

In 1995, Eldered co-founded Recipharm AB and went on to serve as CEO, leading the company through a successful IPO in 2014.

Recipharm AB remains among the top five CDMOs in the world and now includes around 30 manufacturing and development facilities in Europe, India, Israel and North America. Eldered received his MSc in Industrial and Management Engineering at Linköping University.

Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology.

Prokarium's lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK.